Want to see TSE:ACB full AI Analyst Report?
ACB Stock Chart & Stats
C$3.77
C$0.10(2.65%)
At close: 4:00 PM EDT
C$3.77
C$0.10(2.65%)
Day’s Range― - ―
52-Week RangeC$3.59 - C$9.33
Previous CloseN/A
Volume227.23K
Average Volume (3M)324.05K
Market Cap
C$240.34M
Enterprise ValueC$122.39
Total Cash (Recent Filing)C$164.69M
Total Debt (Recent Filing)C$23.86M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 05, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding61,942,146
10 Day Avg. Volume286,221
30 Day Avg. Volume324,046
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.81
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$5.88Price Target Upside55.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.39
Revenue Forecast (FY)C$290.45M
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength & LiquidityMaterial deleveraging and a large cash buffer give Aurora durable financial flexibility. With ~CAD165M cash, no debt and a sizable equity base, the company can fund EU capacity builds, opportunistic M&A or absorb temporary cash flow swings without immediate external pressure.
International Medical Market DiversificationA majority of revenue from regulated international medical markets reduces dependence on Canadian consumer cycles. Strong positions in Germany, Australia and Poland plus market-leading cultivars create a higher-margin, more stable revenue mix versus volatile domestic retail channels.
High Adjusted Margins & EU‑GMP Capacity ExpansionIndustry-leading adjusted gross margins in FY2026 reflect operating leverage in regulated medical channels. Strategic EU‑GMP M&A and capacity builds (Safari, Leuna) create scale and quality supply that support sustained higher-margin international sales as the company shifts away from low-margin domestic lines.
Bears Say
Revenue And Profitability VolatilityThe company’s top-line and earnings have been inconsistent: after prior improvements, FY2026 saw meaningful revenue decline and a swing to large losses. Persistent volatility undermines earnings predictability, complicates reinvestment planning and risks further equity erosion if not stabilized.
Inconsistent Cash GenerationNegative and inconsistent operating and free cash flow increase dependence on liquidity tools (shelf, ATM) and may constrain organic funding for capacity or international expansion. Ongoing FCF deficits elevate execution risk and make multi‑quarter investments more financing‑sensitive.
Canadian Reimbursement Cut Driving FY2027 ResetA structural ~30% reduction in Canadian reimbursement for impacted products materially pressures domestic medical revenue and margins. Management calls FY2027 a reset year, forcing strategic exits of lower‑margin lines and requiring international growth to offset lost domestic profitability.
Aurora Cannabis News
ACB FAQ
What was Aurora Cannabis (US)’s price range in the past 12 months?
Aurora Cannabis (US) lowest stock price was C$3.59 and its highest was C$9.33 in the past 12 months.
What is Aurora Cannabis (US)’s market cap?
Aurora Cannabis (US)’s market cap is C$240.34M.
When is Aurora Cannabis (US)’s upcoming earnings report date?
Aurora Cannabis (US)’s upcoming earnings report date is Aug 05, 2026 which is today.
How were Aurora Cannabis (US)’s earnings last quarter?
Currently, no data Available
Is Aurora Cannabis (US) overvalued?
According to Wall Street analysts Aurora Cannabis (US)’s price is currently Undervalued.
Does Aurora Cannabis (US) pay dividends?
Aurora Cannabis (US) does not currently pay dividends.
What is Aurora Cannabis (US)’s EPS estimate?
Aurora Cannabis (US)’s EPS estimate is -0.18.
How many shares outstanding does Aurora Cannabis (US) have?
Aurora Cannabis (US) has 61,942,146 shares outstanding.
What happened to Aurora Cannabis (US)’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aurora Cannabis (US)?
Currently, no hedge funds are holding shares in TSE:ACB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurora Cannabis Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$5.88 (55.84% Upside)
C$5.88 (55.84% Upside)
Blogger Sentiment
Bullish
TSE:ACB Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth C$66.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 33.8%
Last 30 Days ▲ 33.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.30%
Trailing 12-Months
Company Description
Aurora Cannabis (US)
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facility engineering and design to genetic research, production, and the development of new products, all supported by extensive wholesale and retail networks. For medical users, Aurora offers diverse strains of dried cannabis, oils, capsules, and topical kits. Additionally, it markets a range of accessories, including vaporizers, consumable parts, herb mills (specifically for CanniMed products), grinders, and lockable vaporizer containers. The company is committed to advancing medical cannabis, with ongoing development across oral, topical, edible, and inhalable product categories. Aurora also provides key services such as patient counseling, design and construction assistance, and comprehensive analytical product testing for cannabis, alongside operating CanvasRX, a network dedicated to cannabis counseling and outreach. Its expansive brand family includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The corporate headquarters are located in Edmonton, Canada.
ACB Company Deck
ACB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial performance for FY2026 — double-digit revenue growth, strong adjusted gross margins (64%), 32% growth in adjusted EBITDA to CAD 54M, solid international momentum, accretive M&A (Safari) and a strong cash position (CAD 165M, no debt). However, the company signaled a near-term reset driven by a material (~30%) reduction in Canadian reimbursed pricing effective April 1, which will pressure FY2027 revenue, margins (guidance to mid-to-high 50s) and annual adjusted EBITDA despite targeted investments in higher-margin international markets. Overall, strong historic execution and balance sheet strength outweigh the headwinds, but FY2027 is expected to be transitional as management reallocates resources and expands EU GMP capacity.View all TSE:ACB earnings summariesACB Stock 12 Month Forecast
Average Price Target
C$5.88
▲(55.84% Upside)